Your licensed provider will determine the appropriate dose, frequency, and duration based on your clinical profile

Commonly Reported Research Observations Injection-site redness or irritation Temporary swelling or warmth sensation at the administration site Burning or stinging during administration Temporary skin sensitivity or irritation Mild headaches Temporary fatigue or tiredness Mild nausea Temporary itching or flushing sensations Temporary blue-tinted discoloration beneath the administration area in some research settings Copper-Related Research Considerations Because GHK-Cu is a copper-binding peptide, some research protocols may monitor for: Copper- and zinc-balance variability Increased sensitivity in higher-frequency protocols Temporary skin-related response variability Individual differences in antioxidant-response pathways Research involving prolonged or higher-frequency protocols commonly investigates the inclusion of: Zinc supplementation Vitamin C supplementation alongside GHK-Curelated research models
1988, 255: E322-31
Competitive athletes should be informed about potential sanctions or disqualification risks associated with use of these substances
Expected Benefits & Effects
investigated the eryptosis rate in healthy RBCs treated with different concentrations of IL-6, IL-1, urea, and p -cresol, comparable to their plasma levels in CKD patients, at different time points, and evaluated the cytotoxic effect on RBCs by an in vitro setting